+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Management of atherogenic dyslipidemia of the metabolic syndrome: evolving rationale for combined drug therapy

Management of atherogenic dyslipidemia of the metabolic syndrome: evolving rationale for combined drug therapy

Endocrinology and Metabolism Clinics of North America 33(3): 525

Atherogenic dyslipidemia is prevalent in various conditions associated with central obesity, hypertension, hyperurecemia, and impaired beta-cell function (ie, the metabolic syndrome). Because of clinical trial evidence, most high-risk patients with atherogenic dyslipidemia require statin therapy. Coadministration of drugs targeted to reduction of low-density lipoprotein precursors, however,is likely to improve the metabolic profile of all non-high-density lipoproteins and produce a significant rise in high-density lipoprotein cholesterol. Large-scale clinical trials with combined drug therapy that show coronary heart disease (CHD) risk reduction or improvement in CHD are needed. It is also possible that new drugs are needed to target fatty acid metabolism and inflammation. As understanding of the metabolic origins of atherogenic dyslipidemia increases, it is possible that new targets of therapy will be identified and that new drug combinations will prove to be even more efficacious than those currently available for treatment of this condition.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 035257755

Download citation: RISBibTeXText

PMID: 15262295

DOI: 10.1016/j.ecl.2004.03.013

Related references

Atherogenic dyslipidemia and the metabolic syndrome Pathogenesis and challenge of therapy. Gotto, A M , Jr , Paoletti, R , Smith, L C , Catapano, A L , Jackson, A S Medical Science Symposia Series, Vol 10; Drugs affecting lipid metabolism: Risk factors and future directions : 237-247, 1996

The obesity, metabolic syndrome, and type 2 diabetes mellitus pandemic: II. Therapeutic management of atherogenic dyslipidemia. Journal of Clinical Hypertension 11(9): 520-527, 2009

Relation between atherogenic dyslipidemia and the Adult Treatment Program-III definition of metabolic syndrome (Genetic Epidemiology of Metabolic Syndrome Project). American Journal of Cardiology 95(2): 194-198, 2005

Atherogenic dyslipidemia and the metabolic syndrome. Acta Medica Indonesiana 37(3): 177-183, 2005

Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome. American Journal Of Cardiology. 81(4a): 18b-25b,. 26, 1998

Small LDL, atherogenic dyslipidemia, and the metabolic syndrome. Circulation 95(1): 1-4, 1997

Role of atherogenic dyslipidemia in the development of metabolic syndrome. Medicina Clinica 127(9): 321-324, 2006

Atherogenic dyslipidemia associated with metabolic syndrome and insulin resistance. Clinical Cornerstone 8(Suppl. 1): S21-S27, 2006

Atherogenic dyslipidemia and the metabolic syndrome: pathophysiological mechanisms. Casopis Lekaru Ceskych 147(9): 459-470, 2008

Atherogenic dyslipidemia, metabolic syndrome and cardiovascular risk. Cardiologia 44(10): 885-899, 1999

Dietary carbohydrate restriction induces a unique metabolic state positively affecting atherogenic dyslipidemia, fatty acid partitioning, and metabolic syndrome. Progress in Lipid Research 47(5): 307-318, 2008

Comparative effects of statins on atherogenic dyslipidemia in patients with the metabolic syndrome. Journal of the American College of Cardiology 43(5 Suppl. A): 485A, 2004

Combined therapy with omega-3 fatty acids and niacin in atherogenic dyslipidemia. FASEB Journal 15(4): A639, 2001

What is the best choice for combination therapy in the management of dyslipidemia of metabolic syndrome?. Cardiology 105(3): 139-40; Author Reply 141, 2006

Is it necessary to add fibrate to statin therapy in the management of dyslipidemia of metabolic syndrome?. International Journal of Cardiology 110(2): 276-277, 2006